cetuximab + irinotecan + pazopanib

This is a combination therapy consisting of three drugs with distinct mechanisms of action. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), used in the treatment of metastatic colorectal cancer (mCRC) and head and neck cancers. Irinotecan is a topoisomerase I inhibitor, also used in mCRC. Pazopanib is an oral multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT, approved for advanced renal cell carcinoma and soft tissue sarcoma[2][3][5]. The combination has not been widely studied or approved as a standard regimen for any indication; most clinical data are available for cetuximab plus irinotecan in mCRC, while pazopanib is typically used as monotherapy or with other agents in its approved indications[2][3][6].

Brand names

pazopanib + cetuximab + irinotecan

Other names

cetuximab and irinotecan and pazopanibcetuximab/irinotecan/pazopanib